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Calorie restriction (CR) is neuroprotective in Parkinson’s disease (PD) although themechanisms are unknown. In this study we hypoth-
esized that elevated ghrelin, a gut hormone with neuroprotective properties, during CR prevents neurodegeneration in an 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of PD. CR attenuated the MPTP-induced loss of substantia nigra (SN) dopamine
neuronsandstriatal dopamine turnover inghrelinWTbutnotKOmice, demonstrating that ghrelinmediatesCR’sneuroprotective effect.
CR elevated phosphorylated AMPK and ACC levels in the striatum of WT but not KOmice suggesting that AMPK is a target for ghrelin-
induced neuroprotection. Indeed, exogenous ghrelin significantly increased pAMPK in the SN. Genetic deletion of AMPK1 and 2
subunits only in dopamine neurons prevented ghrelin-induced AMPK phosphorylation and neuroprotection. Hence, ghrelin signaling
throughAMPK in SN dopamine neuronsmediates CR’s neuroprotective effects.We consider targeting AMPK in dopamine neuronsmay
recapitulate neuroprotective effects of CR without requiring dietary intervention.
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Introduction
Parkinson’s disease (PD) is the second most common neurode-
generative disease affecting 160 per 100,000 people with an
estimated incidence number of new cases each year of 16–19 per
100,00 according to the World Health Organization, creating a
substantial medical, social, and financial burden. The motor
symptoms of PD include rigidity and tremor of the extremities,
postural instability, and bradykinesia.
The body mass index of an individual affects PD progression,
as obesity causes dopamine neuronal cell loss in the substantia
nigra (SN) in a mouse model of PD (Choi et al., 2005), and
midlife obesity and type-2 diabetes is associated with a greater
incidence of PD in humans (Chen et al., 2014b). In contrast to
obesity, calorie restriction (CR) attenuates 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity in
both mice (Duan and Mattson, 1999) and nonhuman primates
(Maswood et al., 2004). Indeed, CR in monkeys may delay the
aging process (Colman et al., 2009) and CR in humans has the
potential to slow PD disease progression (Chan et al., 1997), yet
the beneficial effects of CR are dependent on the adherence to
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Significance Statement
The neuroprotective mechanisms of calorie restriction (CR) in Parkinson’s disease are unknown. Indeed, the difficulty to adhere
to CR necessitates an alternative method to recapitulate the neuroprotective benefits of CR while bypassing dietary constraints.
Herewe show that CR increases plasma ghrelin, which targets substantia nigra dopamine tomaintain neuronal survival. Selective
deletion onAMPKbeta1 and beta2 subunits only inDAT cre-expressing neurons shows that the ghrelin-induced neuroprotection
requires activation of AMPK in substantia nigra dopamine neurons. We have discovered ghrelin as a key metabolic signal, and
AMPK in dopamine neurons as its target, which links calorie restriction with neuroprotection in Parkinson’s disease. Thus,
targeting AMPK in dopamine neurons may provide novel neuroprotective benefits in Parkinson’s disease.
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strict dietary constraints that are not always practical and achiev-
able in society. Therefore, it is paramount to identify the key
molecular mechanisms linking CR and neuroprotection to cir-
cumvent the need to adhere to CR.
Ghrelin is synthesized in the stomach where pro-ghrelin is
acylated in the endoplasmic reticulum by the enzyme ghrelin
O-acyltransferase (GOAT). Acyl ghrelin is then released into the
bloodstream where it crosses the blood–brain barrier and binds
to the ghrelin receptor [growth hormone secretagogue receptor
1a (GHSR)] in the brain. In addition to its well knownmetabolic
effects, ghrelin is neuroprotective in PD as ghrelin andGHSRKO
mice exhibited significantly greater loss of SN dopaminergic neu-
rons compared withWT controls in anMPTPmodel of PD (An-
drews et al., 2009). The neuroprotective mechanisms include
reducing apoptosis and suppressing microglial activation and lo-
cal inflammatory responses in the SN (Dong et al., 2009;Moon et
al., 2009).Moreover, postprandial plasma ghrelin concentrations
are lower in human PD patients (Unger et al., 2011), suggesting
clinical relevance.
Plasma ghrelin is elevated during periods of negative energy
balance, including CR and previous studies showed that the an-
xiolytic and antidepressant effects of CR require GHSR signaling
(Lutter et al., 2008). Ghrelin also prevented an excessive decline
in blood glucose levels during CR (Zhao et al., 2010). These stud-
ies provide biological precedents that the ghrelin systemmediates
some of the beneficial effects of CR. Because ghrelin protects
against SN dopaminergic cell loss (Jiang et al., 2008; Andrews et
al., 2009; Moon et al., 2009), we reasoned that elevated plasma
ghrelin during CR contributes to the neuroprotective effects of
CR in PD. Indeed, cells treated with serum from CR rats show
greater survivability, increased mitochondrial function, and mi-
tochondrial biogenesis (Lo´pez-Lluch et al., 2006), arguing that a
hormonal signal mediates the effects of CR on mitochondrial
function and cell survivability. These findings above led us to
hypothesize that increased plasma ghrelin during CR acts on SN
dopamine neurons to restrict SN dopamine neuronal degenera-
tion in a mouse model of PD.
Materials andMethods
Animals.All experiments hereinwere conducted in accordancewithMo-
nash University Animal Ethics Committee guidelines. Mice were main-
tained under standard laboratory conditions with ad libitum access to
food and water at 21°C with a 12 h light/dark cycle unless otherwise
stated.
Experimental protocol. For the first set of experiments, ghrelinWT/KO
mice were individually housed. Male ghrelin WT/KO mice (8–10
weeks old) on a C57BL/6J background were obtained from Regeneron
Pharmaceuticals and bred in theMonash Animal Services facilities. Mice
in ad libitum groups had ad libitum access to food, whereas the remaining
mice were CR to 70% of their baseline food intake. Baseline food intake
was calculated by measuring average food intake over 1 week before the
initiation of the restriction period. CR mice had daily blood glucose and
body weight measurements taken and then given access to a previously
calculated and weighed food pellet1 h before the initiation of the dark
cycle (18:00 h) in an attempt to maintain normal physiological feeding
times for the duration of the experiment (27 d).
In the second set of experiments to test the effect of ghrelin adminis-
tration on neuronal function in the midbrain, we used group housed
maleC57BL/6Jmice (8–10weeks old;MonashAnimal Services, Victoria,
Australia) that had ad libitum access to food and water. C57BL/6J mice
were randomly allocated to receive saline, a low dose of ghrelin (5mg/kg)
or a high dose of ghrelin (15 mg/kg). The mice were injected intraperi-
toneally and the food removed from the cage, they were subsequently
culled 45 min later via decapitation after being deeply anesthetized, then
the brains were dissected and snap frozen (70°C) for HPLC andWest-
ern blot analysis.
To generate mice with selective deletion of AMPK 1 and 2 only in
DAT-expressing dopamine neurons, we crossed Dat-Cre knock-in mice
obtained from The Jackson Laboratory [stock no. 006660; B6.SJL-
Slc6a3tm1.1(cre)bkmn/j] with Ampk  1 subunit (1) and  2 sub-
unit (2) floxed mice (O’Neill et al., 2011). The resultant offspring
(Dat-Cre;Ampk  1fl/fl;Ampk  2fl/fl designated AMPK KO or Ampk
 1fl/fl;Ampk  2fl/fl designated AMPK WT) were used as experimental
mice. To validate this model, AMPK WT and KO mice were also bred
with cre-dependent loxSTOPlox tdTOMATOreportermice [stock num-
ber 007908; B6;129S6-Gt(ROSA)26Sortm14(CAG-tdTomato)Hze/J]. The re-
sultant offspring Dat-Cre;tdTomato or Dat-Cre;Ampk  1fl/fl;Ampk
 2fl/fl;tdTomato mice allow tdTomato visualization of DAT-expressing
neurons that have undergone cre recombination. These mice were also
used for fluorescence-activated cell sorting (FACS). The Dat-Cre;tdTo-
mato were used as AMPK WT mice and Dat-Cre;Ampk  1fl/fl;Ampk
 2fl/fl;tdTomato mice were used as AMPK KO mice. These mice were
culled via inhalation anesthetic and the substantia nigra was collected.
The cells were dissociated using papain (Worthington Kit, LK003150)
following the kit instructions. After collection of5000 tdTomato cells
via FACS sorting using the influx v7 Sorter, the RNA was extracted and
PCR was run to determine the presence/absence of AMPK1 and 2.
In the third set of experiments, to test the effects of ghrelin adminis-
tration in mice lacking AMPK activation, we group housed AMPK WT
and KOmice (8–10 weeks old) with ad libitum access to water. The mice
were administered ghrelin (1 mg/kg) or saline daily at the beginning of
the light cycle for 14 consecutive days. After injections, the food was
subsequently removed for 6 h to prevent excess consumption of calories,
after this period all mice had ad libitum access to food. Previous studies
(Andrews et al., 2009) indicate that if calories are consumed after injec-
tion of acyl ghrelin there is no neuroprotective effect observed. On days 7
and 8, mice were injected with saline or MPTP (30 mg/kg). Mice were
culled on day 14 and perfused for immunohistochemical analysis or fresh
tissue collection for Western blot and HPLC analysis.
MPTP administration. Experimental mice were injected with MPTP
(30 mg/kg, i.p.) dissolved in saline as described previously (Andrews et
al., 2005) over 2 consecutive days. Control animals received sterile saline
using the same timeline. Animals were injected withMPTP or Saline and
perfused 7 d later for immunohistochemical analysis or fresh tissue col-
lection for HPLC and Western blot analysis.
Immunohistochemistry. Free-floating sections were stained with both
tyrosine hydroxylase (TH) and ionized calcium binding adaptor (IBA1)
or glial fibrillary acidic protein (GFAP). All mice were deeply anesthe-
tized and perfused with 0.05% PBS followed by 4% paraformaldehyde
(PFA) to fix the tissue. Brains were stored in PFA overnight then trans-
ferred to a 30% sucrose solution. Coronal sections (30 m thick) of the
entire SN were collected with systematic sampling of every fifth section.
The sections was washed thoroughly in 0.1 M PB and then endogenous
peroxidase activity was blocked using 1% H2O2 in 0.1 M PB for 15 min
and washed again. The tissue was then transferred to 4% normal horse
serumand 0.3%TritonX-100 in 0.1 MPB for 1 h, followed by a secondary
mouse blocking step using AffiniPure Goat Anti-Mouse IgG (HL;
1:200, Jackson ImmunoResearch) to prevent nonspecific binding of
mouse antibodies inmouse tissue. The tissuewas then incubatedwith the
primary antibodies, in this case either anti-TH (mouse, 1:5000; Milli-
pore) and anti-IBA1(rabbit, 1:1000; Wako) or anti-GFAP (rabbit,
1:1000; DAKO) for 24 h at 4°C. Following the primary antibody incuba-
tion the tissue was washed thoroughly and incubated in the secondary
antibody goat anti-mouse IgG (HL) AlexaFluor 488 (1:400; Invitro-
gen) and goat anti-rabbit IgG (HL) AlexaFluor 594 (1:400; Invitrogen)
for fluorescent staining for 90 min at room temperature. The tissue was
then thoroughly washed and mounted directly onto slides and cover-
slipped with anti-fade mounting media.
Stereological investigation of cell number and volume. To quantify the
number of TH neurons, microglia (IBA1 stain), and astrocytes (GFAP
stain) in the SN we used design-based stereology. Using the StereoInves-
tigator software (MicroBrightField) we analyzed both cell number (using
the optical fractionator probe) and cell volume (using the nucleator
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probe). To visualize the cells we used a Zeiss microscope with a motor-
ized stage and a MicroFibre digital camera connected to a computer.
Analysis of blood chemistry.Trunk bloodwas collected via decapitation
from deeply anesthetizedmice and collected into EDTA tubes pretreated
with pefabloc (SC Roche Applied Science) to achieve a concentration
of 1 mg/ml. The blood was then briefly centrifuged and the plasma was
collected and acidified with HCl (final concentration 0.05N). Plasma
ghrelin levels were determined using Active Ghrelin or Des-acyl Ghrelin
Enzyme-Linked Immunoassay Kits (Mitsubishi Chemical Medicine).
Active and des-acyl ghrelin were measured according to kit instructions.
Plasma insulin concentration was determined through an in-house
ELISA assay.
High performance liquid chromatography. We used high-performance
liquid chromatography (HPLC) to identify, separate, and quantify
dopamine (DA) and DOPAC concentrations within samples of striatal
tissue. Striatal (both sides) tissue was rapidly dissected and snap frozen
(70°C). The samples were then sonicated in 0.4 ml cold 0.1 M per-
chloric acid containing internal standard. Following centrifugation, DA
DOPAC and internal standard in the supernatant were extracted on
alumina at pH 8.4, eluted in 0.1 M perchloric acid, separated by reverse-
phase HPLC and detected using electrochemical detection. Both dopa-
mine and DOPAC concentrations in the striatum were calculated by
reference to the internal standard and external standards. The protein
content of each samplewas determined from the centrifuged pellet by the
Lowry method. The concentrations of DA and DOPAC are expressed as
nanograms per milligram of protein present (mean SEM).
Western blot.Whole tissue samples of the SN and striatum or SN4741
cells were processed for Western blot analysis. Briefly, tissue was soni-
cated in RIPA buffer (50 mM Tris.HCl, 150 mM NaCl, 0.1% SDS, 0.5%
sodium deoxycholate, 1% Triton X-100) containing a protease inhibitor
(Sigma-Aldrich), then centrifuged [10,000 rotations per minute (rpm),
10min, 4°C] to remove cell debris, and the supernatantwas collected. For
cell culture studies SN4741 cells were maintained at 37°C in a 5% CO2
humidified environment in DMEM (41965, Life Technologies) supple-
mented with 10% fetal bovine serum, 2 mM glutamine, 100 U/ml peni-
cillin, and 0.1mg/ml streptomycin, 0.6% glucose. Once cells had reached
90–100% confluency, the cells were subcultured.
SN4741 cells were treated with vehicle (compound diluent), 1M acyl
ghrelin (Tocris Bioscience), 6 nM JMV2894 (ghrelin receptor agonist,
Aeterna Zentaris) or 0.5M oligomycin (Sigma-Aldrich) for 5min. Cells
were washed three times with ice-cold PBS and lysed in ice-cold RIPA
lysis buffer (50 mM Tris HCl, pH 7.5 containing 1% NP40, 0.1% SDS,
0.5% sodium deoxycholate, and 150 mM NaCl) with 1% mammalian
protease (Sigma-Aldrich, P8340) and phosphatase inhibitors (Sigma-
Aldrich, P0044; Ho et al., 2013). Cell lysates were incubated at 4°C for 15
min and then centrifuged at 22,000 g for 10 min at 4°C. The superna-
tant was collected and 1 volume of 2 SDS-PAGE sample loading buffer
(Sigma-Aldrich, S3401) was added and left at room temperature for 1 h.
An aliquot was then used to identify the amount of protein present in
each sample using a BCA kit (Pierce) according to kit instructions. The
samples concentrations were then standardized and the supernatants
were mixed with Laemmli buffer, and boiled for 5 min. Samples (20 l)
were loaded onto 10% acrylamide gels and separated by SDS-PAGE. The
separated proteins were then transferred from the gel to the PVDFmem-
brane (Biorad). The blots were then blocked for 1 h in Tris-buffered
saline solution containing 0.1% Tween 20 (TBST) and 5% bovine serum
albumin (BSA). Themembranes were subsequently incubated overnight
at 4°C in TBST with 5% BSA with either of the following antibodies: TH
(1:1000; Milipore), Parkin (1:1000; Santa Cruz Biotechnology), PINK
(1:1000; Santa Cruz Biotechnology), LC3B (1:1000; Cell Signaling Tech-
nology), pACC (1:1000; Cell Signaling Technology) or pAMPK (1:1000;
Cell Signaling Technology), where AMPK (1:1000; Cell Signaling Tech-
nology) antibodies, ACC (1:1000; Cell Signaling Technology) and anti-
actin (1:1000; Abcam) were used as controls. Blots were visualized using
the chemiluminescence method (ECL; GE Healthcare) and levels were
detected using ImageLab Software v4.1, Biorad.
RNA extraction and PCR. After FACS, cells were stored in Qiazol for
RNA extraction. Briefly, chloroform was added, samples were centri-
fuged (12,000 g, 15 min, 4°C) and supernatant was collected. Isopro-
panol and glycogen was added and the samples centrifuged (12,000 g,
10 min, 4°C). The pellet formed was washed with ethanol (75%) and
vortexed. cDNA was synthesized using the iScript cDNA synthesis kit (no.
170-8890, Bio-Rad Laboratories). The cDNA collected was combined with
Mastermixandprimers (eitherAMPK1,AMPK2,orGHSR)andexposed
to a heat block in the Mastercycler. We used TaqMan Gene Expression
Mastermix (Applied Biosystems) andGHSRprimers (GHSR forward: GCT
GCTCACCGTGATGGTAT, reverse: GCTGCTCACCGTGATGGTAT) as
our control. A PCR was required to amplify the AMPK1 and AMPK2
transcripts from the cDNA.We used nested PCR to enhance accuracy using
two PCRs involving outer and inner primers (AMPK1: outer forward:
CCACTCCGAAGAGATCAAGG, reverse: GTGCTGGGTCACAAGAG
ATG; AMPK1: inner forward: CACGACCTGGAAGCGAAT, reverse: CA
TGTAAGGCTCCTGGTGGT; AMPK2: outer forward: GTTATCCGC
TGGTCTGAAGG, reverse: CAGCAGCGTGGTGACATACT; AMPK2:
inner forward: GAGCACCAAGATCCCTCTGA, reverse: GGAAGTAAGG
CTGGGTCACA). This process was repeated with inner primers and then
visualized in a gel mounting media (agarose gel) and exposed to electrical
current (120 V) for 25 min. The results were viewed using gene snap tech-
nology. The specificity of the primers was confirmed using a blast search.
Positive control was hypothalamic tissue from C57BL/6 mice and negative
control contained no cDNA.
Rotarod.Micewere trained before testing by being placed on a rotating
rod (Ugo Basile Rota-Rod 47600), spinning at 4 rpm for 5 min. Lane
width 	 5 cm. On training day, mice were subjected to incrementally
increasing speed over 300 s going from 4 to 40 rpm. Each animal under-
went four trials. The length of time that themice remained on the rodwas
recorded and analyzed.
Statistical analysis. All data are represented as mean SEM. Two-way
ANOVA with a Bonferroni post hoc test was used to determine statistical
significance between treatment and genotype and one-way ANOVAwith
a Tukey post hoc test was used to determine statistical significance be-
tween injection groups. Cell lysate analysis used a two-tailed Student’s t
test. p 0.05 was considered statistically significant.
Results
Effect of CR onmetabolic parameters in ghrelinWT/KO mice
CR significantly elevated acylated (Fig. 1A) and des-acyl plasma
ghrelin in WT, with no detectable levels in KO mice (data not
shown), confirming reports that CR increases plasma ghrelin.
There were no genotypic differences in plasma insulin from ad
libitum or CR mice, although CR significantly reduced plasma
insulin levels compared with ad libitum mice (significant main
effect ad libitum vs CR; Fig. 1B,C). Both body weight and blood
glucosemeasurements exhibited a significant overall reduction in
response to CR (data not shown).
Ghrelin restricts MPTP-induced nigrostriatal damage
during CR
TH neurons
We used the stereological optical fractionator probe to esti-
mate total TH-positive (i.e., dopamine) neurons in the SN.
MPTP administration significantly reduced the number of SN
TH neurons in ad libitum and CR ghrelin WT and KO mice
(Fig. 1D). CR partially attenuated SN TH neuronal loss in
ghrelinWT (Fig. 1E), however, this protective effect was lost in
ghrelin KO mice (Fig. 1F ).
Gliosis
MPTP treatment exhibited a significant elevation in microglia
(IBA1 cells) present in the SN of both genotypes, although CR
did not prevent theMPTP-induced increase of IBA1 cell number
in either ghrelinWT or ghrelin KOmice (Fig. 1G,H). Astrocytes,
as represented by GFAP staining, are the most abundant cell type
found throughout the CNS and play a critical role during cellular
damage tominimize overall cell loss (Hailer et al., 2001). Elevated
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GFAP cells in any specified region indicates greater cellular
damage in that area. MPTP treatment initiated a significant in-
crease in GFAP cells in both ghrelin WT and KO ad libitummice
compared with saline controls (Fig. 1 I, J). CR reduced GFAP
expression in the SN of both MPTP-treated ghrelin WT and KO
mice relative to MPTP ad libitum mice (Fig. 1 I, J), This result
indicates that CR restricts GFAP cell expression in the SN, al-
though this does not appear to be directly mediated by ghrelin.
TH cell volume
To accurately measure cell volume we used the nucleator stereo-
logical probe. There was a significant main effect for MPTP to
Figure 1. Deletion of ghrelin negates the protective effect of CR. A, CR significantly elevates plasma acylated ghrelin. B, C, Overall reduction in plasma insulin levels in response to CR in both
genotypes. D, Representative images showing MPTP-induced TH cell loss in the SN and microglial (IBA) activation. E, F, Stereological quantification of TH neurons in the SN showing CR has no
significant effect in MPTP-treated ghrelin KO mice (F ) but is protective in ghrelin WT mice (E). G, H, Stereological quantification of IBA1 microglia in the SN shows elevated cell number following
MPTP treatment but no effect of genotype. I, J, Stereological quantification of SN GFAP shows that MPTP administration increased GFAP cell number to a lesser extent in ghrelinWT comparedwith
ghrelin KOmice.K, Representative images showingMPTP-induced astrocyte (GFAP) activation in the SN (TH, green; GFAP, red). Data are represented asmean SEM (n	 6–10, two-way ANOVA,
p 0.05). A, Significant compared with saline ad libitum controls. b, Significant compared with MPTP ad libitum controls. Scale bar, 50m.
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reduce average cell volume in ghrelin WT but not ghrelin KO
(Fig. 2A,B). We performed a cell-volume distribution analysis to
determine whether diet or treatment preferentially affected neu-
ronal number within a certain volume range.MPTP treatment to
CR ghrelin WT mice prevented the loss of TH neurons with
volumes between 1000 and 2000 m3 compared with ad libitum
MPTP-treated ghrelin WT mice (Fig. 2C). Remarkably, no ben-
eficial effects of CR on TH neuronal cell volume between were
observed in ghrelin KO mice (Fig. 2D). Thus, ghrelin influences
both TH cell number and cell volume distribution during CR.
HPLC analysis
HPLC analysis of DA in the striatum revealed a significant overall
(p 0.05) reduction with MPTP administration and CR signif-
Figure 2. CR reduces small volume TH cell loss and enhances dopamine turnover in ghrelinWT but not KOmice.A, Overall cell volume for ghrelinWTmice showed a significant ( p 0.05) effect
ofMPTPadministrationbut noeffect of genotypeor diet.B, Ghrelin KOmice showednooverall effect of diet, treatment, or genotype. The reddotted line represents the average cell volumeof ghrelin
WTMPTP-treatedmice.When the cells were separated based on number and volume distribution as shown in C andD, the effect of CR is apparent. C, GhrelinWT have a significant ( p 0.05) effect
between ad libitum and CR cell volume in smaller (1000–2000m3) cells. There was no significant difference in the ghrelin KOmice (D). E,H, CR attenuates striatal DA loss in ghrelin WT but not
ghrelin KO mice after MPTP administration. F, I, MPTP reduced DOPAC with no effect of genotype. G, J, CR reduced the elevation of the DOPAC/DA ratio in MPTP-treated mice compared with ad
libitum, in ghrelin WT but not ghrelin KO mice. a, Significant compared with saline ad libitum controls. b, Significant compared with MPTP ad libitum controls.*p 0.05, **p 0.01. Data are
represented as mean SEM (n	 6–10, two-way ANOVA, p 0.05).
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Figure 3. The protective effect of CR is concomitant with striatal dopamine and elevated pAMPK, an effect not observed in ghrelin KO mice. A, B, Representative Western blot images
of MPTP-induced reduction in TH levels in the SN and striatum. C, D, Quantification of TH levels in ghrelin WT and KO mice showed that MPTP significantly ( p 0.05) reduced TH
expression in the SN. E, F, Quantification of TH levels in the striatum revealed that MPTP significantly ( p 0.05) reduced TH expression, this effect was rescued in CR ghrelin WT mice
but not in KO mice. G, H, Representative Western blot images of pAMPK, AMPK, pACC, and ACC levels in the SN and striatum after either ad libitum or CR paradigms followed by MPTP or
saline treatment. I, M, Quantification of pAMPK/AMPK and pACC/ACC levels in the SN reveals no effect in ghrelin WT mice, however, in KO mice there was a significant ( p 0.05)
reduction betweenMPTP ad libitum andMPTP CR groups (J,N ), showing that CR KOmice could not adapt appropriately to MPTP-induced cell degeneration. K, L, MPTP and CR individually
increased striatal pAMPK/AMPK in ghrelinWTmice but not in ghrelin KOmice, as no change from baseline with either MPTP or CR was observed. O, P, MPTP-induced an increase in striatal
pACC/ACC in ghrelin WT but not ghrelin KO mice, mimicking the effects seen with pAMPK/AMPK. Q, R, Representative Western blots for LC3 I and LC3 II in the SN and striatum of ghrelin
WT and KO mice. S, LC3 II in the SN is significantly reduced in ghrelin WT mice after MPTP treatment; however, this was not observed in ghrelin KO mice (T ). U, V, There was no effect of
CR on LC3 II in the striatum from ghrelinWT and KOmice. However, there was a significant main effect of MPTP to increase LC3 II inWT but not KOmice. a, Significant compared with saline
controls. b, Significant compared with a low dose of ghrelin. *p 0.05, **p 0.01. Data are represented as mean SEM (n	 5–7, one-way ANOVA, p 0.05).
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icantly attenuated the loss of dopamine in WT but not KO mice
(Fig. 2E,H). MPTP also significantly reduced DOPAC in the
striatum, however, there was no effect of diet on DOPAC levels
regardless of genotype (Fig. 2F, I ). CR also prevented the in-
crease in the DOPAC/DA ratio observed afterMPTP in ghrelin
WT ad libitum but not ghrelin KO ad libitummice (Fig. 2G,J ).
TH protein expression
Reduced DA levels in the striatum indicate impaired dopa-
mine synthesis, which is controlled by the rate-limiting en-
zyme TH. In the SN of ghrelin WT and KO mice, MPTP
administration significantly reduced TH protein expression in
both ad libitum fed and CR mice with no protective effect of
CR in either genotype (Figs. 3A,C,D). In the striatum, how-
ever, CR significantly attenuated the reduction in TH protein
levels in MPTP-treated ghrelin WT but not ghrelin KO mice
(Fig. 3B,E,F ). These results highlight that CR has site-specific
effects acting to increase TH in the striatum but not the SN.
Together, these results corroborate with the TH neuronal
counts, cell volume analysis, and HPLC DA content results
indicating that CR has a protective effect only in ghrelin WT
Figure 4. Exogenous ghrelin elevates TH and AMPK activation. A, Representative Western blot images of cultured dopaminergic neurons shows an increase in pAMPK levels in response to acyl
ghrelin, JMV2894 (ghrelin agonist) or oligomycin treatment. Quantification of pAMPK/AMPK levels reveals a significant increase in response to acyl ghrelin (B), JMV2894 (C), and oligomycin (D)
treatment. E, F, RepresentativeWestern blot images of pAMPK, AMPK, pACC, and ACC levels in the SN and striatum.G,H, Quantification of the pAMPK/AMPK and pACC/ACC in the SN (G) in response
to a high dose of ghrelin reveals a significant elevation in response to the high dose of ghrelin. I, J, Quantification of pAMPK/AMPK and pACC/ACC in the striatum reveals no change between saline
and ghrelin doses.K, RepresentativeWestern blot images of TH levels in the SN and striatum. Quantification of TH levels in the SN (L) and striatum (M ) show that intraperitoneal ghrelin significantly
increases TH expression in response to a high dose of ghrelin. RepresentativeWestern blot images of LC3 II expression in the SN and striatum (N ). Quantification of LC3 II revealed high dose caused
a significant increase in the SN (O) but not the striatum (P). a, Significant comparedwith saline/saline controls. b, Significant comparedwith saline/MPTP controls. Data are represented asmean
SEM (n	 6–8, two-way ANOVA, p 0.05).
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Figure5. Ghrelin activates AMPK to elicit neuroprotection in anAMPK-dependentmanner.A, DAT CREmice crossedwith the tdTomato line shows a90%colocalization (B) betweenTH (green)
and tdTomato (red) neurons. Scale bar, 100m. C, Representative tiled image showing TH (green) and tdTomato (red) where each tile represents a 20 image. D, tdTomato labeled TH neurons
were sorted via FACs to show the selective deletion of AMPK1 and AMPK2 in AMPK WT but not AMPK KO mice. Product size for AMPK1 	 386 bp, (Figure legend continues.)
3056 • J. Neurosci., March 9, 2016 • 36(10):3049–3063 Bayliss et al. • Ghrelin Mediate Neuroprotective Effects of CR
mice. Overall, these results imply that ghrelin is responsible
for the protective effects of CR in a mouse model of PD.
Ghrelin influences AMPK activation in the striatum
Ghrelin enhances AMPK activity in the hypothalamus (Andrews
et al., 2008) and AMPK also increases mitochondrial biogenesis
and function in the periphery (Bergeron et al., 2001; Horvath et
al., 2011). Thus, we reasoned that the neuroprotective actions of
CR induce a ghrelin-dependent increase inAMPK function in SN
TH neurons. We found that both metabolic (CR) and chemical
(MPTP) stress increased AMPK phosphorylation (pAMPK/
AMPK ratio) and subsequent acetyl CoA carboxylase (ACC) in
the striatum, but not the SN as seen for TH expression, in ghrelin
WT but not ghrelin KO mice (Fig. 3G–P). CR in ghrelin KO
MPTP-treatedmice significantly reduced AMPK and ACC phos-
phorylation in the SN compared with ghrelin KOMPTP ad libi-
tum mice (Fig. 3 J,N). The maintenance of autophagy is one
downstream effect of AMPK activation (Mihaylova and Shaw,
2011), therefore we examined LC3 II, the membrane-bound
form of autophagosomes (Kimura et al., 2007). We observed
significantly reduced LC3 II in the SN of CR ghrelin WT mice
compared with ad libitum controls (Fig. 3S), with a significant
overall elevation in response to MPTP in striatum (Fig. 3U). No
effect was observed in the SN (Fig. 3T ) or striatum (Fig. 3V ) of
ghrelin KO mice. The LC3 II results in the SN are inversely
related to SN TH cell counts suggesting there is less autopha-
gosome formation required in cells with less MPTP-induced
degeneration.
PINK1 and Parkin regulate mitophagy and mutations in
PINK and Parkin cause early onset PD, therefore, we also mea-
sured the expression of these two proteins in the SN and striatum
from CR and ad libitum ghrelin WT and KO mice. PINK1 and
Parkin expression showed a significant reduction in protein ex-
pression post-MPTP administration in the striatum with no sig-
nificant effect of CR or genotype (data not shown). There was no
change in protein levels in response to metabolic state, MPTP, or
genotype in the SN (data not shown).
Exogenous ghrelin influences the phosphorylation of AMPK
and ACC
To support the notion that increased endogenous ghrelin is the
critical to CR-induced neuroprotection, we examined the effects
of exogenous acyl ghrelin on AMPK and ACC phosphorylation
both in vivo and in vitro. The addition of either acyl ghrelin or the
ghrelin agonist JMV2894 increased AMPK activation in cultured
dopaminergic cell line SN4741 (Fig. 4A–D).
For in vivo studies, we injected acyl ghrelin intraperitoneally at
two different doses (low, 5mg/kg; high, 15mg/kg). The high dose
of acyl ghrelin significantly increasedAMPKandACCphosphor-
ylation in the SN (Fig. 4E,G,H). However, there was no signifi-
cant difference in the striatum in response to either a low or high
dose of acyl ghrelin (Fig. 4F, I,J). This is in contrast to the effect of
CR on AMPK activation, as we observed a significant difference
in the striatum but not the SN.
Injection of intraperitoneal acyl ghrelin at a high dose signif-
icantly increased TH expression in both the SN and striatum (Fig.
4K–M). Moreover, intraperitoneal acyl ghrelin increased LC3 II
in the SN but not the striatum (Fig. 4N–P). There was no change
in PINK1 expression in either the SN or the striatum (data not
shown). Parkin expression remained unchanged in the SN; how-
ever, in the striatum there was a significant increase with a high
dose of acyl ghrelin (data not shown). These results indicate that
peripheral acyl ghrelin injection affects AMPK and ACC phos-
phorylation, as well as TH, Parkin, and LC3 II protein expression
in the nigrostriatal system.
Exogenous ghrelin requires AMPK in dopamine neurons to
elicit neuroprotection
To prove that ghrelin-induced neuroprotection requires AMPK
activation in SN dopamine neurons, we generated a novel mouse
line in which AMPK activation was disabled in dopaminergic
neurons. These mice were generated by cross breeding Dat-Cre
mice with Ampk  1fl/fl; Ampk  2fl/flmice to generate AMPKWT
and AMPK KO mice. AMPK 1 and 2 are regulatory subunits
required for AMPK activity (O’Neill et al., 2011). To determine
the specificity of the knock-out, we bred AMPKWT andKOwith
Rosa26loxSTOPlox tdTomato reporter mice to generate Dat-
Cre;tdTomato and Dat-Cre;Ampk  1fl/fl;Ampk  2fl/fl;tdTomato
mice. TH and tdTomato coexpression in the SN was90% (Fig.
5A–C), indicating cre recombination had occurred in 90% of
SN TH neurons. Deletion of AMPK1 and AMPK2 in dopa-
mine neurons was confirmed by FACS of tdTomato-labeled neu-
rons from midbrain dissections from Dat-Cre;tdTomato and
Dat-Cre;Ampk  1fl/fl;Ampk  2fl/fl;tdTomato mice, and nested
PCR for AMPK1 and AMPK2 (Fig. 5D). Positive bands for
both AMPK1 and AMPK2 were observed in AMPK WT but
not AMPK KOmice (Fig. 5D). As a positive control, nested PCR
for GHSR was performed to confirm the presence of the ghrelin
receptor in both AMPKWT and KO mice (Fig. 5D).
To show that ghrelin elicits neuroprotection in amousemodel
of PD, we chronically administered acyl ghrelin to AMPK WT
and KO mice. In AMPK WT mice, acyl ghrelin administration
significantly attenuated TH cell loss in MPTP-treated mice (Fig.
5E,F). This effect was abolished in the AMPKKOmice (Fig. 5G).
Acyl-ghrelin reduced IBA1 cell number in AMPKWTMPTP-
treated mice (Fig. 5H), however, no significant effect was ob-
served in AMPK KO mice (Fig. 5I). A similar pattern was
observed with GFAP cells, in which acyl ghrelin reduced GFAP
cell number in AMPKWT but not AMPK KO mice (Fig. 5 J,K).
Despite the attenuated TH cell loss in the acyl ghrelin-treated
AMPK WT mice there was no overall change in cell volume or
distribution (Fig. 6A–D). HPLC analysis of dopamine and
DOPAC in the striatum revealed that acyl ghrelin attenuated the
MPTP-induced loss of dopamine and prevented the MPTP-
induced rise in the DOPAC/dopamine ratio in AMPK WT but
notAMPKKOmice (Fig. 6E–J). Changes inmotor behaviorwere
determined using an accelerating Rotarod by measuring latency
to fall. There was no overall change between saline or ghrelin-
treated AMPKWT and KO mice without MPTP treatment (Fig.
6K,L). When pretreated with saline and given MPTP there was
no effect of genotype (Fig. 6M), however, there was a protective
effect of ghrelin administration before MPTP in AMPK WT but
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(Figure legend continued.) AMPK2	 395 bp. The ghrelin receptor (GHSR) is unaffected by
deletion of AMPK1 and AMPK2 in SN TH neurons. E, Representative images showing TH
neurons from AMPKWT and KOmice after chronic ghrelin treatment. F, G, Stereological quan-
tification of TH neurons from AMPKWT (F) and KO (G) mice shows a protective effect of ghrelin
treatment in WT but not KO mice. H, Stereological quantification of IBA1 microglia in the SN
shows that ghrelin suppresses IBA1 cells relative to saline controls following MPTP treatment;
however, this is not observed in AMPK KOmice (I). J, K, Stereological quantification of GFAP in
the SN shows that ghrelin attenuates theMPTP-induced increase in GFAP cell numbers in AMPK
WT (J) but not AMPK KO (K) mice. L, Representative images showing MPTP-induced astrocyte
(GFAP) activation in the SN (TH, green; GFAP, red). a, Significant compared with saline/saline
controls. b, Significant compared with saline/MPTP controls. Data are represented as mean
SEM (n	 6–8, two-way ANOVA, p 0.05). Scale bar, 100m.
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Figure 6. Chronic ghrelin injection enhances dopamine turnover and behavioral outcomes in AMPKWT but not KOmice. A,B, Overall cell volume showing no reduction in response to genotype
or treatment. When cells were separated based on number and volume distribution as shown in C and D, there was no overall effect of genotype or treatment. HPLC data show that ghrelin
significantly attenuates the MPTP-induced decrease in striatal dopamine concentration in AMPK WT but not AMPK KO mice (E, H). MPTP reduced DOPAC with no effect of genotype (F, I). Ghrelin
treatment significantly attenuates the MPTP-induced increase in the DOPAC/dopamine ration in AMPK WT but not AMPK KO mice (G, J). K–N, Behavioral analysis (Figure legend continues.)
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not KOmice (Fig. 6N). Collectively, these experiments highlight
that ghrelin activates AMPK in SN dopamine neurons, restricts
dopaminergic cell loss, maintains striatal dopamine concentra-
tions and promotes locomotor behavior afterMPTP treatment to
provide a neuroprotective effect.
We previously showed that intraperitoneal ghrelin can elicit
an increase in the pAMPK/AMPK and pACC/ACC ratio in SN
(Fig. 4G,H) and that chronic ghrelin treatment to AMPK WT,
but not AMPKKO is neuroprotective in amousemodel of PD. In
further support of this neuroprotection, ghrelin treatment atten-
uated theMPTP-induced loss of TH in both the SN and striatum
ofAMPKWTbut notAMPKKOmice (Fig. 7A–F). To determine
whether chronic ghrelin differentially affected AMPK and subse-
quent ACC phosphorylation, we measured the pAMPK/AMPK
and pACC/ACC ratio in AMPK WT and KO mice in response
chronic daily ghrelin injections. There was no effect of chronic
ghrelin treatment on the pAMPK/AMPK (Fig. 7G, I, J) or the
pACC/ACC ratio (Fig. 7M,N) in the SN of either AMPKWT or
AMPK KOmice. However, MPTP treatment elicited an increase
in the pAMPK/AMPK (Fig. 7H,K,L) and pACC/ACC ratios (Fig.
7O,P) in the striatum of AMPK WT mice, but not AMPK KO
mice. The mitophagy proteins PINK1 and Parkin (data not
shown) and the autophagosome marker LC3 II were not signifi-
cantly different between genotypes and treatment (Fig. 7Q–V).
Discussion
CR protects against a number of pathological conditions includ-
ing diabetes, cancer, heart disease, and neurodegeneration. In
PD, an alternate-day feeding schedule where rats consumed 30–
40% less calories than ad libitum controls was neuroprotective
post-MPTP exposure (Duan and Mattson, 1999). Mice also elic-
ited a neuroprotective responsewhen alternate day feeding begun
after exposure to MPTP (Holmer et al., 2005). Primates with a
chronic overall 30% reduction in food intake were also resistant
to MPTP-induced neurotoxicity (Maswood et al., 2004). These
studies prove that CR is beneficial in PD; however, the difficulty
to adhere toCRnecessitates an alternativemethod to recapitulate
the neuroprotective benefits of CR while bypassing dietary con-
straints. Evidence from cells treated with serum from CR rats
suggests a hormonal factor improvesmitochondrial function and
cell viability (Lo´pez-Lluch et al., 2006). We hypothesized that
ghrelin may be this hormonal factor, because CR increases
plasma acyl ghrelin (Lutter et al., 2008) and ghrelin restricts de-
generation in PD (Andrews et al., 2009). In this study, we show
for the first time that ghrelin mediates the neuroprotective effect
of CR in amousemodel of PDby attenuatingMPTP-induced loss
of TH neurons, TH neuronal volume and dopamine content in
the striatum. Further, we show that AMPK in SN dopamine neu-
rons is a molecular target for ghrelin’s neuroprotective effects, as
deletion of AMPK1 and2 subunits only in dopamine neurons
prevented ghrelin-induced neuroprotection. These results sug-
gest that ghrelin, and its downstream target AMPK, has a poten-
tial therapeutic application in the treatment of PD to mimic the
neuroprotective effect of CR without the need for strict dietary
constraints.
Although this is the first study to show that ghrelin mediates
the neuroprotective effects of CR in a mouse model of PD, it
supports an increasing number of observations that ghrelin re-
stricts the negative consequences of CR or negative energy bal-
ance. For example, ghrelin prevents the excessive decline in blood
glucose during severe CR (Zhao et al., 2010) and the anxiolytic
effects of CR require GHSR signaling (Lutter et al., 2008). A re-
cent study byMcFarlane et al. (2014) shows that adult-ablation of
ghrelin secreting cells has no effect on food intake, body weight,
and fed blood glucose. Only under CR did these mice show def-
icits in blood glucose. Moreover, CR reduces hippocampal cell
death in GHSRWT but not GHSR KOmice (Walker et al., 2015)
and CR induces neurogenesis in a GHSR-dependent manner
(Hornsby et al., 2016). Collectively, these studies show that the
major function of ghrelin is to act as a feedback signal of CR
(negative energy balance) andmaintain physiological and neuro-
logical function during this time.
Our data show that AMPK in SN dopamine neurons is a mo-
lecular target of ghrelin during CR to maintain neuronal func-
tion. First, metabolic stress (CR) and/or toxic stress (MPTP)
promoted AMPK activity in striatal dopamine nerve terminals in
ghrelin WT but not ghrelin KO. The ability of MPTP to increase
AMPK activity is supported by previous studies in mice and cells
(Choi et al., 2010). AMPK enhances mitochondrial function and
biogenesis (Reznick and Shulman, 2006), as such, we suggest
CR-induced AMPK phosphorylation at the nerve terminal pro-
motes neuronal energy metabolism and supports ongoing dopa-
minergic neuronal activity, which is supported by the reduced
striatal DOPAC/dopamine ratio of both CR ghrelin and AMPK
WT mice but not their respective KO mice. Moreover, AMPK
activity diminishes with age (Reznick et al., 2007) consistent with
the age-related neurodegeneration that contributes to the onset
of PD. Thus, the ability of CR to maintain AMPK activity in a
ghrelin-dependentmannermay restrict age-related decline in the
nigrostriatal system. This possibility is further strengthened by
data showing that plasma ghrelin and ghrelin’s function dimin-
ishes with age, an effect that can be reversed with CR (Englander
et al., 2004; Smith et al., 2007; Sun et al., 2007; Yang et al., 2007;
Takeda et al., 2010). Further, PDpatients have reduced postpran-
dial plasma ghrelin levels (Unger et al., 2011).
In cultured dopaminergic neurons both acyl ghrelin and a
ghrelin agonist elicited a robust increase in AMPK activation.
Acute acyl ghrelin injection in vivo increased both AMPK and
ACC phosphorylation in the SN but not the striatum. This is the
first in vivo study that shows ghrelin activates AMPK activity in
the midbrain, similar to numerous reports showing ghrelin acti-
vates AMPKactivity in the hypothalamus (Andersson et al., 2004;
Kola et al., 2005; Andrews et al., 2008). As noted above, CR drives
ghrelin-induced AMPK phosphorylation in the striatum, but not
the SN, yet acute ghrelin injection in vivo increased AMPK phos-
phorylation in the SN but not the striatum. We consider this
discrepancy may be due to chronically elevated ghrelin versus an
acute ghrelin injection. Chronically high plasma ghrelin, as seen
in CR ghrelin WT mice, activates SN dopamine neurons via the
GHSR which then facilitates and propagates AMPK phosphory-
lation in areas of metabolic need, in this case striatal nerve termi-
nals to prevent degeneration. Although acute injection of ghrelin
increases the pAMPK/AMPK ratio in the SN after 45 min, this
narrow time frame presumably prevents propagation of AMPK
phosphorylation in the striatum. It is important to note that the
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(Figure legend continued.) showing latency to fall on an accelerating rotarod. K, L, No differ-
ence in latency to fall in mice not exposed to MPTP. In mice given MPTP, latency to fall is not
effected by genotype in mice pretreated with saline (M). However, in mice pretreated with
ghrelin there is a significant protective effect in AMPKWT but not KO as evidence by increased
latency to fall (N). a, Significant compared with saline/saline controls. b, Significant compared
with saline/MPTP controls. Data are representedasmeanSEM(n	6–12, two-wayANOVA,
p 0.05).
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Figure7. Chronic ghrelin injections increase nigrostriatal TH expression andAMPKactivation in anAMPK-dependentmanner.A,B, representativeWestern blot images of the SN (A) and striatum
(B) showing TH levels. In both the SN and the striatum there is a significant protective effect of ghrelin administration on TH levels in AMPKWTmice (C, E) that is absent in AMPK KOmice (D, F). G,
H, Representative Western blot images showing pAMPK, AMPK, pACC, and ACC levels in the SN (G) and striatum (H). There was no significant change in the pAMPK/ (Figure legend continues.)
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ghrelin receptor, GHSR, is abundantly expressed in the SN with
little or no expression in the striatum (Zigman et al., 2006).
Importantly, we conclusively demonstrate that AMPKactivity
in dopamine neurons is necessary for ghrelin-induced neuropro-
tection in a mouse model of PD. We generated a model in which
AMPK1 and AMPK2 were successfully deleted in DAT-
expressing neurons. Deletion of both AMPK1 and AMPK2 in
muscle ablated AMPK phosphorylation and lead to impaired
glucose homeostasis (O’Neill et al., 2011). Using the model,
we showed that ghrelin prevents nigrostriatal degeneration in
MPTP-treatedAMPKWTbut not AMPKKOmice, clearly estab-
lishing AMPK as a critical molecular mechanism mediating the
neuroprotective effects of ghrelin on the nigrostriatal system.Our
genetic model also deletes AMPK1 and AMPK2 in all DAT-
cre-expressing neurons including populations not associated
with PD, such as the hypothalamic and VTA dopamine neurons.
However, MPTP predominantly affects SN dopamine neurons
(Seniuk et al., 1990; Muthane et al., 1994), which strengthens the
specific and important neuroprotective actions of ghrelin on
AMPK activity in the SN. We should note that we did not detect
a change in pAMPK/AMPK ratio in the SNor striatumof chronic
ghrelin-treated AMPK WT or KO mice, whereas acute ghrelin
injection affected the pAMPK/AMPK ratio in the SN. There are
many potential reasons for this including the dosage and time of
tissue collection after last injection. However, the most plausible
reason is due to the tissue collection, because we measured
pAMPK/AMPK in a dissected piece of tissue, of which only a
small proportion represents SN dopamine neurons. Neverthe-
less, in response to MPTP treatment AMPK WT mice produced
an increase in pAMPK/AMPK ratio in the striatum, which was
not observed in AMPK KO. In fact, the significant main effect of
MPTP to suppress AMPK phosphorylation, independent from
ghrelin treatment, in both the SN and striatum of AMPK KO
illustrates the important role of AMPK1 and AMPK2 in SN
dopamine neurons to combat cellular stress caused by MPTP.
Moreover, CR ghrelin KO mice also did not show a compensa-
tory increase in MPTP-induced AMPK phosphorylation in the
striatum, further supporting the idea that ghrelin targets AMPK
in SN dopamine neurons during CR to prevent degeneration.
Intriguingly, we noted differential effects of CR and ghrelin
treatment on gliosis. In the CR experiment, the microglial re-
sponse to MPTP was not different in ghrelin WT and KO mice
despite the greater TH cell loss in ghrelin KOmice. This is some-
what unexpected given microglia become activated to remove
neuronal damage by phagocytosis (Neumann et al., 2009). It is
possible that a threshold level of cell loss elicits the same micro-
glial response, perhaps mediated by the release of caspase signal
(Burguillos et al., 2011). Moreover, GFAP cell number was in-
creased after MPTP and suppressed in CR mice regardless of
genotype. In primates CR elicited a protective effect by limiting
astrogliosis in the hippocampus (Sridharan et al., 2013). These
results suggest that the effects of CR on gliosis are independent
from changes in plasma ghrelin. However, chronic ghrelin-
treatment to AMPKWT and AMPK KOmice showed that ghre-
lin reduced microglia and GFAP in AMPK WT but not AMPK
KO mice treated with MPTP. This effect of ghrelin treatment is
consistent with in vitro studies that indicate ghrelin directly in-
hibits glial activation to diminish the inflammatory response (Lee
and Yune, 2014). Moreover, that lack of an effect in AMPK KO
mice suggests ghrelin acts directly on AMPK in SN dopamine to
restrict microglia and GFAP expression, a hypothesis supported
by studies showing that AMPK activity influences gliosis (Lu et
al., 2010; Yi et al., 2011; Chen et al., 2014a; Han et al., 2014; Zhou
et al., 2014).
This is the first study to show the important neuroprotective
in vivo actions of AMPK in dopamine neurons, although a num-
ber of studies implicate AMPK as an intracellular energy sensor
promoting neuroprotection in models of PD. For example,
AMPK attenuates mitochondrial and dopaminergic dysfunction
in drosophilamodels of PD (Ng et al., 2012), and pharmacological
activators of AMPK, such as Resveratrol (Jin et al., 2008) and
guanidino-propionic acid (Horvath et al., 2011), were neuropro-
tective in vivo. Metformin treatment in cells overexpressing 
synuclein, to model PD, also activated AMPK and restricted cell
death (Dulovic et al., 2014). However, in vitro studies recently
demonstrated that AMPK overactivation has a detrimental effect
and promoted  synuclein accumulation and inhibited neurite
growth (Jiang et al., 2013).
In conclusion, CR is perhaps the most robust and reproduc-
ible mechanism to enhance lifespan and promote healthy aging.
The exact mechanism/s that achieve this are currently unknown,
however, several theories include altered stress response path-
ways, altered signaling pathways involving SIRT1, FOXO, UCP2,
and AMPK (Andrews, 2010) as well as alterations in metabolic
hormones such as ghrelin and insulin. We consider CR induces a
mild stress and encourages compensatorymetabolic changes that
favor improved intracellular mitochondrial health. Although CR
promotesmetabolic health and reduces neurodegeneration there
is a poor compliance in the general population, as it requires
20–40% reduced calorie intake over years to achieve maximal
benefits. Consequently, there is a need to recapitulate these ben-
eficial effects without restricting calorie intake. We have discov-
ered a novel pathway where circulating ghrelin, which is elevated
during CR, has a protective role in the nigrostriatal system via
enhanced AMPK activity. This ghrelin-induced neuroprotection
is dependent on AMPK activity in dopamine neurons. Future
research should focus on exploiting this pathway to determine
the in vivo neuroprotective effects that restrict neurodegenera-
tion without the need to adhere to strict dietary regimes.
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